KCNA3 and epilepsy: Small molecules capable of modulating voltage-gated calcium, sodium, and potassium channels have been developed to treat pain, stroke, migraine, epilepsy, cancer, and autoimmune disorders amongst others; and are thought to provide a good basis for the development of novel MS treatments [119–121].